Icotrokinra vs Octreotide
Overview
Icotrokinra is primarily a immune support peptide, while Octreotide is used for hormonal.
This page compares Icotrokinra and Octreotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Icotrokinra | Octreotide | |
|---|---|---|
| Category | Immune Support | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | — | 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) |
| Frequency | — | Every 4 weeks (LAR); two to four times daily (immediate-release) |
| Reported benefits | — | Reduction of growth hormone and IGF-1 in acromegaly, suppression of carcinoid flushing and diarrhea, control of VIPoma-associated watery diarrhea, antiproliferative effect on low-grade neuroendocrine tumors, reduction of urinary 5-HIAA biomarkers |
| Reported side effects | — | Gallstones and biliary sludge, diarrhea, nausea, abdominal discomfort, sinus bradycardia, hyperglycemia, hypoglycemia, hypothyroidism, steatorrhea, injection-site pain |
Key differences
Primary use. Icotrokinra is categorised under Immune Support, while Octreotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Icotrokinra: FDA-approved. Octreotide: FDA-approved.
Dosing. Typical dosing for Icotrokinra is not catalogued. Octreotide is typically dosed at 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) (Every 4 weeks (LAR); two to four times daily (immediate-release)).
Can you stack them?
Some protocols combine peptides, but stacking Icotrokinra and Octreotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Icotrokinra and Octreotide?
- Icotrokinra is primarily a immune support peptide, while Octreotide is used for hormonal. Icotrokinra is FDA-approved for one or more indications, whereas Octreotide is FDA-approved for one or more indications.
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- What is Octreotide used for?
- FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988.
- Can you take Icotrokinra and Octreotide together?
- Some users combine peptides within a single protocol, but stacking Icotrokinra and Octreotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Icotrokinra or Octreotide FDA-approved?
- Icotrokinra is FDA-approved for one or more indications. Octreotide is FDA-approved for one or more indications.
Read the full articles
- Icotrokinra — full monograph: mechanism, research, dosing & references
- Octreotide — full monograph: mechanism, research, dosing & references